Company
Shield Therapeutics PLC
LON:STX
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer ® /Feraccru ® (ferric maltol). The group has launched Accrufer® in the US and Feraccru ® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical for the development and commercialization of Accrufer ® / Feraccru ® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co in the Republic of Korea, and with KYE Pharmaceuticals in Canada.
175 stories · page 3 of 9
Shield Therapeutics says lead product expected to gain Korean regulatory approval in 2023
The Korean Food and Drug Administration has agreed that a single pharmacokinetic study is the only additional requirement to support a New Drug Application submission for Accrufer
Shield Therapeutics’ lead product Accrufer has shelf-life extended to 48 months
FDA approval provides additional supply-chain flexibility for pharmaceutical company’s lead product
Peel Hunt thinks the commercial prospects for Shield Therapeutics' Accrufer anaemia treatment remain "very good"
The Peel Hunt analysts noted that Shield's first half 2022 revenues were £2.0mln with prescriptions for Accrufer up 350% from a year earlier
Shield Therapeutics sees revenues climb as US sales ramp up
The average net selling price for its anaemia treatment Accrufer rose by 350% to US$152
Shield Therapeutics PLC jumps as AOP confirms stake
Austria-based AOP, which specialises in treatments for relatively rare or orphan treatments, lent Shield US$10mln in June
Shield Therapeutics completes the formalities on US$10mln loan
AOP Health International Management has provided the facility
Shield Therapeutics partner makes new drug submission in Canada
The regulator is expected to complete its review by the middle of next year